Acupuncture for Dry Eye

This study has been completed.
Sponsor:
Collaborators:
DongGuk University
DONGSHIN University Oriental Hospital
Information provided by:
Korea Institute of Oriental Medicine
ClinicalTrials.gov Identifier:
NCT01105221
First received: April 13, 2010
Last updated: January 7, 2011
Last verified: April 2010
  Purpose

The purpose of this study is to assess whether acupuncture is more effective than artificial tear drop in the treatment of dry eye.


Condition Intervention Phase
Dry Eye
Device: Acupuncture
Drug: Refresh Plus
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Acupuncture for Dry Eye: a Multicenter Randomized Controlled Trial With Active Comparison Intervention (Artificial Tear Drop) Using a Mixed Method Approach

Resource links provided by NLM:


Further study details as provided by Korea Institute of Oriental Medicine:

Primary Outcome Measures:
  • Ocular Surface Disease Index (OSDI) [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    This questionnaire is a 12-item instrument for ocular irritation and impact on visual function in dry eye sufferers. It can provide quantifiable results of dry eye symptom frequency and vision-related functioning. Korean version of the OSDI questionnaire will be used. Follow up measurement will be assessed after 4, 5, 9 and 13 weeks from the first visit.


Secondary Outcome Measures:
  • Visual analogue scale (VAS) for self-assessment of ocular discomfort [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    Self-reports on ocular symptoms concomitant with dry eye, such conditions as ocular itching, foreign body sensation, burning, pain and dryness as well as for blurred vision, sensation of photophobia, ocular redness and sensation of tearing. Follow up measurement will be assessed after 4, 5, 9 and 13 weeks from the first visit.

  • Schirmer I test with anaesthesia [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    This ia a method for checking basic tear secretion. Schirmer test paper (Color Bar™ Eagle Vision, USA) will be inserted on the lateral third of the lower eyelid with the participant's eye closed for five minutes. Follow up measurement will be assessed after 5 weeks and 13 weeks from the first visit.

  • Tear Film Break Up Time (BUT) [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    This is a method for observing tear film stability. Sodium fluorescein (2.5%) will be instilled in both eyes and the tear break-up time (the interval between the last complete blink and the first appearance of a dry spot or disruption in the tear film) will be measured. Follow up measurement will be assessed after 5 weeks and 13 weeks from the first visit.

  • General Assessment by acupuncture practitioner and participants [ Time Frame: Up to 5 weeks ] [ Designated as safety issue: No ]
    Practitioners and participants will evaluate the improvement of ocular symptoms after treatment. They can chose one of the following 5 grades: Excellent, Good, Fair, Poor and Aggravation.

  • Self reports about experiences of using other dry eye-related treatments after the end of each intervention. [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    For cost-effective analysis, all experience of using other dry eye-related treatments after the end of each intervention should be reported by participants. It contains frequency of hospital visit and treatments methods. Follow up measurement will be assessed after 9, 13 weeks from the first visit.

  • Quality of life (QOL) [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    One questionaire for QOL, related to dry eye, is asked. Follow up measurement will be assessed after 4, 5, 9 and 13 weeks from the first visit.

  • Case reports on adverse events for the evaluation of safety [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: Yes ]
    Adverse events, adverse acupuncture or artificial tear drop reaction, serious and unexpected adverse acupuncture or artificial tear drop reaction and serious adverse event will be reported by participants and checked by practioners in every visit. Number of participants with adverse events will also be recorded.

  • Qualitative analysis (additional study) [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    Questionaires with open-ended question about personal experiences for dry eye, acupuncture treatment and usage of artificial tear drop will be distributed to every participant of both group. Follow up measurement will be assessed after 4 and 13 weeks from the first visit.

  • Cost-effectiveness analysis between acupuncture and artificial tear drop treatment (additional study) [ Time Frame: Up to 13 weeks ] [ Designated as safety issue: No ]
    Cost-effectiveness of acupucnture will be analyzed using Ocular Surface Disease Index (OSDI) variable, comparing the cost of artificial tear drops. the Cost which all participants will use for dry eye during the trial period, will be recorded in every visit.


Estimated Enrollment: 150
Study Start Date: April 2010
Study Completion Date: January 2011
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acupuncture Device: Acupuncture
Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
Active Comparator: Artificial tear drop Drug: Refresh Plus
Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
Other Name: Brand name: ALLERGAN

Detailed Description:

Dry eye is one of the common diseases in ophthalmology. It affects not only patients' daily activities such as reading, carrying out professional work, using the computer, watching television, and driving, but also bodily health conditions such as bodily pain, discomfort and lower energy and vitality.

Currently, artificial tears are easily subscribed or used in the shape of OTC drugs. However, preservatives in artificial tears may exacerbate ocular surface inflammation and the safety of anti-inflammatory treatment is not well established.

Acupuncture, one of the most popular CAM interventions, showed some favourable effects over artificial tears for dry eye in several randomised controlled trials (RCTs). The evidence obtained from these trials is quite limited because all of these RCTs were conducted under high risk of biases. Therefore, well-designed RCTs are needed to establish the efficacy of acupuncture for dry eye.

In a clinical trial, cost-effectiveness and qualitative researches can be carried out parallely. Through this kind of mixed method approaches, various compartments, consisting acupuncture treatment effects are able to be revealed totally.

In this context, the investigators designed a multi-center randomized controlled trial, comparing acupuncture treatment and artificial tear drop with immunoassay for the change of tear cytokine concentration, cost effectiveness study and qualitative research in a mixed method approach.

  Eligibility

Ages Eligible for Study:   19 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have had dry eye syndromes in single eye or in both eyes (ICD-10 : H04.1). He or she must have both of the conditions below:

    1. Patients who have dry eye symptoms such as itching, ocular foreign body sensation, ocular burning, ocular pain, ocular dryness, blurred vision, sensation of photophobia, ocular redness, sensation of tearing
    2. Patients whose tear film break-up time is below 10 seconds and Schirmer I test results is below 10mm/5sec.

Exclusion Criteria:

  • Patients who have defects of the eyelid or eyelashes
  • Acute infection of the eyelid, eyeball or eye accessories
  • Stevens-Johnson syndrome
  • Vitamin A deficiency
  • Eye or accessory defects due to external injuries
  • A past history of surgical operation related to the eye in last three months
  • Punctual occlusion
  • Current usage of contact lenses
  • Sequelae of facial palsy,
  • Current usage of anti-inflammatory eye drops in the last two weeks
  • Pregnancy
  • Using history of traditional medicinal treatment such as acupuncture, moxibustion and herbal medicine in the last one month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01105221

Locations
Korea, Republic of
Clinical Research Center of DongGuk Univ. Internaltional Hospital
Goyang, Gyeonggi, Korea, Republic of, 410-773
Clinical Research Center of Korea Institute of Oriental Medicine
Daejeon, Korea, Republic of, 301-724
Clinical Research Center of DongShin Univ. Oriental Hospital
Gwangju, Korea, Republic of, 503-232
Sponsors and Collaborators
Korea Institute of Oriental Medicine
DongGuk University
DONGSHIN University Oriental Hospital
Investigators
Principal Investigator: Sun-Mi Choi, Dr Korea Institute of Oriental Medicine
  More Information

No publications provided by Korea Institute of Oriental Medicine

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kim, Ki-ok/ President of KIOM, Korea Institute of Oriental Medicine (KIOM)
ClinicalTrials.gov Identifier: NCT01105221     History of Changes
Other Study ID Numbers: KI1001
Study First Received: April 13, 2010
Last Updated: January 7, 2011
Health Authority: South Korea: Institutional Review Board

Keywords provided by Korea Institute of Oriental Medicine:
Acupuncture
Dry eye
Artificial tear drop
Mixed method approach
Qualitative study
Cost effectiveness analysis
Tear cytokine analysis

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2014